Therapeutics Articles
Researchers are taking a closer look at intravenous immune globulin for its potential to stop the progression of multiple complex conditions from lupus to multiple sclerosis.
Many years after the first products were introduced in the late 1990s, the need for fibrin sealants continues to increase.
Antibiotics are the most commonly prescribed drugs worldwide. But now, widespread antimicrobial resistance caused by environments, hosts and overmedication may soon be the demise of these "wonder drugs."
Studies are shedding light on this long-misunderstood and devastating condition that may soon have approved treatments to help prolong cancer patients’ lives.
The U.S. market for IVIG continues to grow well over 5 percent annually. What is driving the market demand?
Gene therapy is the one remaining therapeutic option for treating severe combined immunodeficiency by correcting it at its most fundamental genetic level.
Advancements in stem cell therapy may soon eliminate surgeries and cure disease, but first, the debate between two different schools of thought concerning how best to proceed needs to be resolved.
New extended half-life products represent a powerful new tool for improving the care and quality of life for persons with hemophilia.
As it has since the first commercially produced factor VIII concentrate transformed the lives of U.S. hemophilia A patients, innovation is still the life-blood of this industry.
Explore the history and trace the development of BabyBIG, the life-saving immunotherapy for infant botulism.
Still in its infancy, precision medicine holds out hope for moving directly from diagnosis to an effective tailor-fit treatment for each individual patient.
New long-acting therapeutics are changing the way hemophilia is managed, creating more choice and better treatment compliance.